U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H21FN2O4.C6H14N4O2
Molecular Weight 534.5804
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVONADIFLOXACIN ARGININE

SMILES

N[C@@H](CCCNC(N)=N)C(O)=O.C[C@H]1CCC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCC(O)CC4

InChI

InChIKey=WIFOPRFVQIVWTB-YBVIJTQESA-N
InChI=1S/C19H21FN2O4.C6H14N4O2/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21;7-4(5(11)12)2-1-3-10-6(8)9/h8-11,23H,2-7H2,1H3,(H,25,26);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t10-;4-/m00/s1

HIDE SMILES / InChI

Molecular Formula C6H14N4O2
Molecular Weight 174.201
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C19H21FN2O4
Molecular Weight 360.3794
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Levonadifloxacin is the S-(-) isomer of the benzoquinolizine fluoroquinolone nadifloxacin and is two- to four-fold more active than the racemic mixture. Levonadifloxacin is a potent antibacterial agent against Gram-positive bacteria especially against methicillin resistance Staphylococcus aureus. It also possesses potent bactericidal activity against other resistant variants like quinolone-resistant Staphylococcus aureus, vancomycin and glycopeptide intermediate Staphylococcus aureus and vancomycin resistant Staphylococcus aureus. Intravenous dosage form developed to treat complicated skin and skin structure infections and has recently completed Phase III studies in India and Phase I studies in USA.

Approval Year

PubMed

PubMed

TitleDatePubMed
Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.
2004 Aug
Activity of the new quinolone WCK 771 against pneumococci.
2005 Jan
Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria.
2005 Oct
The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
2006 Nov
Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone.
2019 Jan
Identification of metabolites of novel Anti-MRSA fluoroquinolone WCK 771 in mouse, rat, rabbit, dog, monkey and human urine using liquid chromatography tandem mass spectrometry.
2019 Jul
Patents
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:20:29 GMT 2023
Edited
by admin
on Sat Dec 16 18:20:29 GMT 2023
Record UNII
U2RV55F5O0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVONADIFLOXACIN ARGININE
Common Name English
L-ARGININE, (5S)-9-FLUORO-6,7-DIHYDRO-8-(4-HYDROXY-1-PIPERIDINYL)-5-METHYL-1-OXO-1H,5H-BENZO(IJ)QUINOLIZINE-2-CARBOXYLATE (1:1)
Common Name English
WCK-771
Common Name English
L-ARGININE, MONO((5S)-9-FLUORO-6,7-DIHYDRO-8-(4-HYDROXY-1-PIPERIDINYL)-5-METHYL-1-OXO-1H,5H-BENZO(IJ)QUINOLIZINE-2-CARBOXYLATE)
Common Name English
LEVONADIFLOXACIN ARGININE SALT
Common Name English
Code System Code Type Description
FDA UNII
U2RV55F5O0
Created by admin on Sat Dec 16 18:20:30 GMT 2023 , Edited by admin on Sat Dec 16 18:20:30 GMT 2023
PRIMARY
CAS
306748-89-0
Created by admin on Sat Dec 16 18:20:30 GMT 2023 , Edited by admin on Sat Dec 16 18:20:30 GMT 2023
PRIMARY
PUBCHEM
9850037
Created by admin on Sat Dec 16 18:20:30 GMT 2023 , Edited by admin on Sat Dec 16 18:20:30 GMT 2023
PRIMARY
EPA CompTox
DTXSID60184714
Created by admin on Sat Dec 16 18:20:30 GMT 2023 , Edited by admin on Sat Dec 16 18:20:30 GMT 2023
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY